Document:

Exhibit 4.3

 

DESCRIPTION OF REGISTRANT’S SECURITIES
REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

 

The following description of our capital
stock is intended as a summary only and therefore is not a complete description of our capital stock. This description is based
upon, and is qualified by reference to, our amended and restated certificate of incorporation (the “Amended Certificate”),
our amended and restated bylaws (the “Amended Bylaws”) and applicable provisions of Delaware corporate law. You should
read our Amended Certificate and Amended Bylaws, which are filed as exhibits to our Annual Report on Form 10-K, to which
this exhibit is also appended.

 

Our authorized capital stock consists of
35,000,000 shares of common stock, par value $0.0001 per share, and 2,000,000 shares of preferred stock, par value $0.0001 per
share.

 

Our common stock is the only class of securities
registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

 

Common
Stock

 

Holders of our
common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative
voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders
entitled to vote in the election. Subject to the supermajority votes for some matters, other matters shall be decided by the affirmative
vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting
on such matter. Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of
directors, subject to any preferential dividend rights of any series of preferred stock that we may designate and issue in the
future.

 

In the event of
our liquidation or dissolution, the holders of common stock are entitled to receive on a pro rata basis our net assets available
for distribution to stockholders after the payment of all debts and other liabilities, subject to the prior rights of any holders
of outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption or conversion rights. Our
outstanding shares of common stock are validly issued, fully paid and nonassessable. The rights, preferences and privileges of
holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred
stock that we may designate and issue in the future.

 

Preferred
Stock

 

Under the terms
of our Amended Certificate our board of directors is authorized to direct us to issue shares of preferred stock in one or more
series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges
and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences,
of each series of preferred stock.

 

The purpose of
authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated
with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with
possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a
third party to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock.

 

     

     

    

 

Registration
Rights

 

Under our registration
rights agreement dated as of December 19, 2014, holders of 2,273,847 shares of common stock, or their transferees, have the
right to require us to register their shares under the Securities Act of 1933, as amended (the “Securities Act”) so
that those shares may be publicly resold, or to include their shares in any registration statement we file, in each case as further
described below.

 

Demand
Registration Rights

 

If holders of more
than 50% of the registrable securities request us to file a registration statement under the Securities Act for a public offering
of such shares of registrable securities having an aggregate offering price of at least $10,000,000, we must, within ten days after
the receipt of such notice, notify all holders of registrable securities of such request and shall use its reasonably diligent
efforts to register under the Securities Act the registrable securities of all holders who so request within 90 days after
the date of our notice; provided, however, that we are obligated to register only shares of common stock pursuant to the agreement.
We are obligated to effect a maximum of two such demand registrations.

 

Piggyback/Incidental
Registration Rights

 

Whenever we propose
to register any common stock for our own or others’ account under the Securities Act for a public offering for cash, other
than a registration relating to employee benefit plans, we must give each holder of registrable securities prompt written notice
of its intent to do so. Upon the written request of any such holder given within 10 days after receipt of such notice, we
will cause to be included in such registration all of the registrable securities that such holder requests; provided, however,
that we are obligated to register only shares of our common stock pursuant to the agreement. If we are advised in writing by any
managing underwriter of the securities being offered pursuant to any registration statement that the number of shares to be sold
by persons other than us is greater than the number of such shares that can be offered without adversely affecting the offering,
we may reduce pro rata the number of shares of registrable securities offered for the accounts of such persons to a number deemed
satisfactory by such managing underwriter; and a managing underwriter will have the right to exclude registrable securities entirely
pursuant to the preceding clause.

 

Form S-3
Registration Rights

 

If, at a time when
Form S-3 (or any successor thereto) is available for such registration, we receive from holders of more than 15% of the registrable
securities a written request or requests that we effect a registration on Form S-3 of registrable securities having an aggregate
offering price of at least $5,000,000 (based on the then current public market price), we will promptly give written notice of
the proposed registration to all other holders of registrable securities and, as soon as reasonably practicable, effect such registration
and all such related qualifications and compliances as may be requested and as would permit the sale and distribution of all registrable
securities as are specified in such request and any written requests of other holders given within 10 days after receipt of
such notice; provided, however, that the Company shall not be obligated to effect any such registration pursuant to the agreement:
(i) if Form S-3 is not available for such offering by the applicable holders; or (ii) if we furnish to the applicable
holders a certificate signed by the chief executive officer stating that in the good faith judgment of the board of directors,
it would be seriously detrimental to us and our stockholders for such Form S-3 registration to be effected at such time, in
which event we will have the right to defer the filing of the Form S-3 registration statement for a period of not more than
120 days after receipt of the request of the holder or holders; provided, however, that we may not utilize this right more
than twice in any 12-month period. We are not obligated to file more than two registrations under this provision.

 

Other
Provisions and Expenses

 

A registrable security
will cease to be a registrable security when (i) a registration statement covering such registrable security has been declared
effective by the SEC and it has been disposed of pursuant to such effective registration statement; or (ii) such registrable
security could be sold pursuant to Rule 144 (or any successor or comparable provision) without any volume restriction.

 

    2

     

    

 

Other than underwriting
discounts and commissions and certain other expenses, we will be required to pay all expenses incurred by us related to any registration
effected pursuant to the exercise of these registration rights. These expenses may include all registration and filing fees, printing
expenses, fees and disbursements of our counsel, reasonable fees and disbursements of a counsel for the selling stockholders and
blue sky fees and expenses.

 

Warrant
to Purchase Common Stock

 

In connection with the initial public offering
of our common stock (the “IPO”), we issued to ThinkEquity, a division of Fordham Financial Management, Inc. (the “Representative”),
a warrant (the “Representative’s Warrants”) to purchase 100,000 shares of our common stock at an exercise price
of $7.50 per share (125% of our IPO price per share). The exercise price and number of shares issuable upon exercise of the warrants
may be adjusted in certain circumstances including in the event of a stock dividend or our recapitalization, reorganization, merger
or consolidation. However, the warrant exercise price or underlying shares will not be adjusted for issuances of shares of common
stock at a price below the warrant exercise price. The Warrant is exercisable at any time, from time to time, in whole or in part,
during the four-year period commencing one year from the effective date of the registration statement related to this offering.

 

The Representative’s Warrants and
the shares of common stock underlying the Representative’s Warrants have been deemed compensation by FINRA and are, therefore,
subject to a 180-day lock-up pursuant to FINRA Rule 5110(g)(1). The Representative or permitted assignees under such rule may not
sell, transfer, assign, pledge, or hypothecate the Representative’s Warrants or the securities underlying the Representative's
Warrants, nor will the representative engage in any hedging, short sale, derivative, put, or call transaction that would result
in the effective economic disposition of the Representative's Warrants or the underlying shares of common stock for a period of
180 days from January 28, 2020. Additionally, the Representative's Warrants may not be sold, transferred, assigned, pledged, or
hypothecated for a 180-day period following January 28, 2020, except to any underwriter and selected dealer participating in the
offering and their bona fide officers or partners. The Representative's Warrants provide for registration rights upon request,
in certain cases. The demand registration right provided will not be greater than five years from the effective date of this registration
statement in compliance with FINRA Rule 5110(f)(2)(G)(iv). The piggyback registration right provided will not be greater than seven
years from the effective date of this registration statement in compliance with FINRA Rule 5110(f)(2)(G)(v). We will bear all fees
and expenses attendant to registering the securities issuable on exercise of the Representative’s Warrants other than underwriting
commissions incurred and payable by the holders.

 

Anti-Takeover
Effects of Delaware Law and Our Amended Certificate and Amended Bylaws

 

Some provisions
of Delaware law, our Amended Certificate and Amended Bylaws could make the following transactions more difficult: an acquisition
of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the removal of our incumbent
officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions
that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide
for payment of a premium over the market price for our shares.

 

These provisions,
summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also
designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that
the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited
proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals
could result in an improvement of their terms.

 

Authorized
but Unissued Shares

 

Our authorized
but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval. These additional
shares may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital and corporate
acquisitions. The existence of authorized but unissued shares of common stock and preferred stock could render more difficult or
discourage an attempt to obtain control of a majority of our common stock by means of a proxy contest, tender offer, merger or
otherwise.

 

    3

     

    

 

Stockholder
Meetings

 

Any action to be
taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written
consent.

 

Requirements
for Advance Notification of Stockholder Nominations and Proposals

 

Stockholders seeking
to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders
must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder's notice.

 

Delaware
Anti-Takeover Statute

 

We are subject
to Section 203 of the General Corporation Law of the State of Delaware, which prohibits persons deemed to be “interested
stockholders” from engaging in a “business combination” with a publicly held Delaware corporation for three years
following the date these persons become interested stockholders unless the business combination is, or the transaction in which
the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally,
an “interested stockholder” is a person who, together with affiliates and associates, owns, or within three years prior
to the determination of interested stockholder status did own, 15% or more of a corporation's voting stock. Generally, a “business
combination” includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested
stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance
by the board of directors.

 

Choice
of Forum

 

The Court of Chancery
of the State of Delaware is the exclusive forum in which we and our directors may be sued by our stockholders, to the fullest extent
permitted by law, for:

 

		·	any derivative action or proceeding brought on our behalf;

		·	any action asserting a breach of fiduciary duty;

		·	any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our Amended Certificate,
or our Amended Bylaws; or

		·	any action asserting a claim against us that is governed by the internal affairs doctrine.

 

Our Amended Bylaws
do not apply to suits brought to enforce a duty or liability created by the Securities Act or the Exchange Act, or any other claim
for which federal courts have exclusive jurisdiction.

 

These choice of
forum provisions may limit a stockholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with
us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims. Alternatively,
if a court were to find either choice of forum provision contained in our Amended Bylaws to be inapplicable or unenforceable in
an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business,
results of operations, and financial condition.

 

    4

     

    

 

Advance
Notice Requirements

 

Our Amended Bylaws
establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including
proposed nominations of persons for election to the board of directors. Stockholders at an annual meeting will only be able to
consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the
board of directors or by a stockholder who was a stockholder of record on the record date for the meeting, who is entitled to vote
at the meeting and who has given our Secretary timely written notice, in proper form, of the stockholder's intention to bring that
business before the meeting. Although our Amended Bylaws do not give the board of directors the power to approve or disapprove
stockholder nominations of candidates or proposals regarding other business to be conducted at a special or annual meeting, our
Amended Bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not
followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors
or otherwise attempting to obtain control of us.

 

Transfer Agent and Registrar

 

The transfer agent and registrar for our
common stock is American Stock Transfer & Trust Company, LLC.

 

National Securities Exchange Listing

 

Our common stock listed on NYSE American
under the symbol “ANVS.”

 

    5Exhibit 10.1

 

SECOND
AMENDED AND RESTATED

EMPLOYMENT AGREEMENT

 

EMPLOYMENT
AGREEMENT effective as of March 24, 2020 (this “Agreement”) between Annovis Bio, Inc. (the “Company”),
a Delaware corporation, and Maria L. Maccecchini (the “Executive”).

 

Background:

 

The parties desire to enter into this Agreement
to provide for the employment of the Executive by the Company from and after the Commencement Date and for certain other matters
in connection with such employment, all as set forth more fully in this Agreement. Certain capitalized terms used in this Agreement
have the respective meanings given to them in Exhibit A hereto.

 

Terms:

 

NOW,
THEREFORE, in consideration of the premises and covenants set forth herein, and intending to be legally bound hereby, the
parties to this Agreement hereby agree as follows:

 

1.            Position and Duties; Board Seat. 

 

(a)          Position and Duties. The Company agrees that the Executive shall be employed by the Company to serve as Chief
Executive Officer and President of the Company. The Executive shall report to the Board of Directors of the Company (the “Board”).
The Executive agrees to be so employed by the Company and agrees to devote substantially all of her business time, attention, skill
and efforts to perform services for the Company and to faithfully and diligently discharge and fulfill the Executive’s duties
hereunder to the best of her abilities. In so doing, the Executive shall perform such executive, managerial, administrative and
financial functions as are required to develop the Company’s business and to perform other duties assigned to the Executive
by the Board that are consistent with the Executive’s title as Chief Executive Officer and President. The Executive shall
perform her duties hereunder primarily at the Company’s principal offices. In the performance of her duties, the Executive
shall travel to such other places at such times as the needs of the Company may from time-to-time dictate or be desirable.

 

(b)          Other Activities. Notwithstanding Section 1(a), the Executive may engage in other business and professional activities
to the extent that they do not interfere with the Executive’s obligations under this Agreement, provided that each of those
activities is first disclosed to and approved by the Board. The parties acknowledge that activities in which the Executive is currently
engaged have been disclosed to and approved by the Board.

 

(c)           Board Seat. The Executive serves as a member of the Board. The Executive agrees to resign as a member of the
Board if the Executive resigns or is terminated as the Chief Executive Officer of the Company for any reason.

 

     

     

    

 

2.            Term. The Executive’s employment
under this Agreement shall commence on the Commencement Date and shall end when terminated pursuant to Section 4.

 

3.            Compensation.

 

(a)           Base Salary. During the term of the Executive’s employment under this Agreement, the Executive shall be
paid an annual salary at the rate of $420,000 (the “Base Salary”), retroactive to January 1, 2020, payable in accordance
with the Company’s payroll practices and policies in effect from time to time and subject to applicable withholding of income
taxes, social security taxes and other such other payroll deductions as are required by law or applicable employee benefit programs.
The Board shall review the Executive’s Base Salary for annual increases, commencing with the Base Salary for the 2021 calendar
year.

 

(b)           Annual Bonus. With respect to each fiscal year of the Company during the continued full-time employment of the
Executive hereunder, commencing with the 2020 fiscal year, the Executive will be eligible to be considered for an annual performance
bonus (the “Annual Bonus”) in an amount of up to 50% of the Executive’s Base Salary. The Annual Bonus, if any,
will be awarded by the Board in its sole discretion based on the achievement of Company and personal performance goals established
by the Board on an annual basis, following consultation with the Executive and shall take into account the stock options and any
other equity incentive awards that vest in the year the bonus is paid. Any Annual Bonus awarded to the Executive hereunder may
be paid in cash or in equity of the Company, as determined by the Board in its sole discretion, and will be payable or issuable,
less applicable taxes and withholdings, not later than two and one-half months after the end of the fiscal year to which the Annual
Bonus relates in accordance with the Company’s customary practices for annual bonus payments.

 

(c)           Equity Incentives. Subject to the approval of the Board, the Executive shall be granted stock options under the
Equity Incentive Plan and shall be considered for future stock option awards as specified on Exhibit B hereto. In addition,
the Executive shall be eligible to participate in future equity incentive programs established by the Company from time to time
in the future in accordance with the terms of those programs.

 

(d)           Vacation and Fringe Benefits. The Executive shall be entitled to participate in all vacation and other fringe
benefit programs of the Company to the extent and on the same terms and conditions as are accorded to other senior management employees
of the Company.

 

(e)           Reimbursement of Other Expenses. The Company shall reimburse the Executive for the reasonable and necessary out-of-pocket
business expenses incurred by the Executive for or on behalf of the Company in furtherance of the performance of the Executive’s
duties hereunder in accordance with the Company’s policies as approved by the Board from time to time, subject in all cases
to the Company’s requirements with respect to reporting and documentation of such expenses.

 

(f)            Section 409A. If any reimbursement under this Section 3 is not exempt from Section 409A of the Internal Revenue
Code of 1986, as amended (the “Code”) then (i) any reimbursement in one calendar year shall not affect the amount that
may be reimbursed in any other calendar year; (ii) a reimbursement (or right thereto) may not be exchanged or liquidated for another
benefit or payment; and (iii) a reimbursement shall be made no later than the end of the calendar year following the calendar year
in which the Executive incurred the related expense.

 

    2

     

    

 

4.            Termination.

 

(a)           Death or Disability. The Executive’s employment with the Company shall automatically terminate effective
as of the date of the Executive’s death, and the Company may terminate the employment of the Executive immediately upon written
notice to the Executive in the event of the Disability of the Executive. In the event of termination of the Executive’s employment
due to death or Disability, the Company shall not have any further obligation or liability under this Agreement except that the
Company shall pay to the Executive or the Executive’s estate (as applicable): (i) any portion of the Executive’s Base
Salary for the period up to the date of employment termination that has been earned but remains unpaid; (ii) any expenses properly
incurred but not yet reimbursed, including, without limitation, the reimbursements provided for in Section 3(e); (iii) any benefits
that have accrued to the Executive under the terms of the employee benefit plans of the Company, which benefits shall be paid in
accordance with the terms of those plans (the payments in clauses (i) through (iii) collectively, the “Accrued Obligations”);
and (iv) in the event of a termination of employment due to the Executive’s death, the Annual Bonus awarded pursuant to Section
3(b), if any, with respect to the fiscal year prior to the fiscal year of termination, to the extend unpaid (the “Earned
Bonus”). The Accrued Obligations shall be paid on the first payroll date following the last date of employment to the extent
administratively feasible and, if not, then on the second payroll date following the last date of employment. The Earned Bonus,
if any, will be paid when it would have been paid had Executive remained employed with the Company.

 

(b)           Termination of the Executive’s Employment for Cause. The Company may terminate the employment of the Executive
for Cause immediately upon written notice of such termination to the Executive. If the Executive’s employment with the Company
is terminated by the Company for Cause, the Company shall not have any further obligation or liability under this Agreement except
for the Accrued Obligations. The Accrued Obligations shall be paid on the first payroll date following the last date of employment
to the extent administratively feasible and, if not, then on the second payroll date following the last date of employment.

 

(c)           Involuntary Termination.

 

(i)            The Company may terminate the employment of the Executive for any reason other than one specified in Section 4(a) or Section
4(b) immediately upon written notice of termination to the Executive, and the Executive may terminate her employment with the Company
for Good Reason immediately upon providing written notice of such termination to the Company. Either of such terminations shall
be deemed an “Involuntary Termination” for purposes of this Agreement.

 

(ii)           Upon the occurrence of an Involuntary Termination, in addition to the Accrued Obligations, and subject to the execution
by the Executive of a release in the form of Exhibit C hereto (the “Release”) and the compliance by the Executive
with the Release and all terms and provisions of this Agreement and the Confidentiality and Invention Assignment Agreement (as
defined in Section 5) that survive the termination of the Executive’s employment by the Company the Executive shall be entitled
to receive (A) severance payments in an amount equal to the Base Salary in effect on the termination date for a period of 12 months;
plus (B) monthly reimbursement (upon presentation of proof of payment) for the medical insurance premiums at the same level as
was in effect on the termination date until the earlier of (1) the end of such 12-month period or (2) the date the Executive
becomes eligible for medical benefits through another employer; provided, however, that if such Involuntary Termination shall occur
upon the closing of a Change of Control or within 12 months thereafter: (A) the severance shall be payable in a single lump sum
and (B) the Executive shall also be entitled to receive an amount equal to the projected target amount of the Executive’s
Annual Bonus for the calendar year in which the Executive’s employment termination occurs payable in a single lump sum, such
lump sum payments to be made in each case on the first regularly scheduled payroll date that occurs on or after 60 days after the
effective date of such employment termination. Any payments due pursuant to this Section 4(c), other than the Accrued Obligations,
shall commence as soon as administratively feasible within 60 days after the date of the Executive’s termination of employment
provided the Executive has timely executed and returned the Release and, if a revocation period is applicable, the Executive has
not revoked the Release; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar
year, the severance payments shall begin to be paid in the second calendar year. On the date that payments pursuant to clauses
(A) and (B) commence, the Company will pay the Executive in a single lump sum payment, less applicable taxes and withholding, the
payments that the Executive would have received on or prior to such date but for the delay imposed by the immediately preceding
sentence, with the balance of the payments to be paid as originally scheduled. The Accrued Obligations will be paid on the first
payroll date following last date of employment to the extent administratively feasible and, if not, then on the second payroll
date following the last date of employment.

 

    3

     

    

 

(iii)          Notwithstanding anything to the contrary set forth elsewhere in this Agreement, the Executive may not terminate her employment
with the Company for Good Reason pursuant to this Section 4(c), and shall not be considered to have done so for any purpose of
this Agreement, unless (A) the Executive, within 60 days after the initial existence of the act or failure to act by the Company
that constitutes “Good Reason” within the meaning of this Agreement, provides the Company with written notice that
describes, in particular detail, the act or failure to act that the Executive believes to constitute “Good Reason”
and identifies the particular event specified in the definition of “Good Reason” on Exhibit A that the Executive
contends is applicable to such act or failure to act; (B) the Company, within 30 days after its receipt of such notice, fails or
refuses to rescind such act or remedy such failure to act so as to eliminate “Good Reason” for the termination by the
Executive of the Executive’s employment relationship with the Company; and (C) the Executive actually resigns from the employ
of the Company on or before that date that is 12 months after the initial existence of the act or failure to act by the Company
that constitutes “Good Reason.” If the requirements of the immediately preceding sentence are not fully satisfied on
a timely basis, then the resignation by the Executive from the employ of the Company shall not be deemed to have been for “Good
Reason,” the Executive shall not be entitled to any of the benefits to which the Executive would have been entitled if the
Executive had resigned from the employ of the Company for “Good Reason,” and the Company shall not be required to pay
any amount or provide any benefit that would otherwise have been due to the Executive under this Section 4(c) had the Executive
resigned with “Good Reason.”

 

(d)           Other Termination by the Executive. The Executive may terminate the Executive’s employment for any reason
other than for Good Reason upon 30 days’ prior written notice of termination to the Company. In the event the Executive shall
terminate the Executive’s employment pursuant to this Section 4(d), the Company shall not have any further obligation or
liability under this Agreement, except for the Accrued Obligations, which shall be paid on the first payroll date following last
date of employment to the extent administratively feasible and if not, then on the second payroll date following the last date
of employment. The Company shall not have the right following Executive’s provision of notice to terminate the Executive’s
employment prior to the end of the notice period unless the Company pays the Executive for the full notice period.

 

(e)           Base Salary Continuation. The Base Salary continuation set forth in Section 4(c) above shall be intended either
(i) to satisfy the safe harbor set forth in the Treas. Regs. 1.409A-1(b)(9)(iii), or (ii) be treated as a Short-term Deferral as
that term is defined Treas. Regs. 1.409A-1(b)(4). To the extent such continuation payments exceed the applicable safe harbor amount
or do not constitute a Short-term Deferral, the excess amount shall be treated as deferred compensation under Code section 409A
and as such shall be payable pursuant to the following schedule: such excess amount shall be paid via standard payroll in periodic
installments in accordance with the Company’s usual practice for its senior executives. Solely for purposes of Code section
409A, each installment payment is considered a separate payment. Notwithstanding any provision in this Agreement to the contrary,
in the event that the Executive is a “specified employee” as defined in Code section 409A, any continuation payment,
continuation benefits or other amounts payable under this Agreement that would be subject to the special rule regarding payments
to “specified employees” under Section 409A(a)(2)(B) of the Code shall not be paid before the expiration of a period
of six months following the date of the Executive’s termination of employment or before the date of the Executive’s
death, if earlier.

 

(f)            Parachute Provisions. In the event a Change of Control occurs, the Company will engage an independent accounting
firm (the “Accounting Firm”) at its expense to determine whether the Executive received, is entitled to receive or
will become entitled to receive any benefits or payments in the nature of compensation (within the meaning of Section 280G(b)(2)
of the Code) (the “Total Payments”), and whether the Total Payments will be subject to the tax (the “Excise Tax”)
imposed by Section 4999 of the Code. If the Total Payments will be subject to the Excise Tax, the aggregate present value of the
Total Payments shall be reduced (but not below $1) if reducing the Total Payments will provide the Executive with a greater net
after-tax amount than would be the case if no reduction was made. Any reduction shall be effected in accordance with Section 409A
of the Code.

 

    4

     

    

 

5.             Restrictive Covenants. Concurrently with the execution hereof, and as a condition
of employment, the Executive shall execute and deliver an Employee Confidential Disclosure, Invention Assignment, Non-Competition,
Non-Solicitation and Non-Interference Agreement (the “Confidentiality and Invention Assignment Agreement”).

 

6.             No Conflicts. The Executive represents
and warrants that the Executive is not party to any agreement, contract or understanding, whether of employment, consultancy or
otherwise, in conflict with this Agreement or which would in any way restrict or prohibit the Executive from undertaking or performing
services for the Company or otherwise from entering into or performing this Agreement or the Confidentiality and Invention Assignment
Agreement.

 

7.             Full Agreement. This Agreement and
the Confidentiality and Invention Assignment Agreement (including the Exhibits hereto), constitute the entire agreement of the
parties concerning its subject matter and supersedes all other oral or written understandings, discussions, and agreements, including
but not limited to the Amended and Restated Employment Agreement dated as of May 10, 2019 between the Executive and the Company,
but shall not supersede, or otherwise be deemed to terminate, any confidentiality agreements, non-disclosure obligations or restrictive
covenants in favor of the Company in effect immediately prior to the Commencement Date. This Agreement may be modified only in
a writing signed by both parties. The Executive acknowledges that she has read and fully understand the contents of this Agreement
and the Confidentiality and Invention Assignment Agreement and is executing it after having an opportunity to consult with legal
counsel.

 

8.             Amendments. Any amendment to this Agreement
shall be made in writing and signed by the parties hereto.

 

9.             Enforceability. If any provision of
this Agreement shall be invalid or unenforceable, in whole or in part, then such provision shall be deemed to be modified or restricted
to the extent and in the manner necessary to render the same valid and enforceable, or shall be deemed excised from this Agreement,
as the case may require, and this Agreement shall be construed and enforced to the maximum extent permitted by law as if such provision
had been originally incorporated herein as so modified or restricted or as if such provision had not been originally incorporated
herein, as the case may be.

 

10.          Construction. This Agreement shall
be construed and interpreted in accordance with the internal laws of the Commonwealth of Pennsylvania.

 

11.          Assignment. 

 

(a)           By the Company. The rights and obligations of the Company under this Agreement shall inure to the benefit of,
and shall be binding upon, the successors and assigns of the Company. This Agreement may be assigned by the Company without the
consent of the Executive.

 

(b)           By the Executive. This Agreement and the obligations created hereunder may not be assigned by the Executive,
but all rights of the Executive hereunder shall inure to the benefit of and be enforceable by the Executive’s heirs, devisees,
legatees, executors, administrators and personal representatives. Any attempted assignment in violation of this Section 11(b) shall
be null and void.

 

    5

     

    

 

12.          Notices. All notices required or permitted
to be given hereunder shall be in writing and shall be deemed to have been given when mailed by certified mail, return receipt
requested, or delivered by a national overnight delivery service addressed to the intended recipient as follows:

 

	 	If to the Company:
	 	 
	 	Annovis Bio, Inc.

1055 Westlakes Drive

Berwyn, PA  19312

Attention:  Chairman of the Board
	 	 
	 	If to the Executive:
	 	 
	 	Maria L. Maccecchini

1223 Foxglove Lane

West Chester, PA  19380-5854

 

Any party may from time to time change its address for the purpose
of notices to that party by a similar notice specifying a new address, but no such change shall be deemed to have been given until
it is actually received by the party sought to be charged with its contents.

 

13.          Waivers. No claim or right arising
out of a breach or default under this Agreement shall be discharged in whole or in part by a waiver of that claim or right unless
the waiver is supported by consideration and is in writing and executed by the aggrieved party hereto or such party’s duly
authorized agent. A waiver by any party hereto of a breach or default by the other party hereto of any provision of this Agreement
shall not be deemed a waiver of future compliance therewith, and such provisions shall remain in full force and effect.

 

14.          Survival of Covenants. The provisions
of Section 4 through this Section 14 shall survive the termination of the Executive’s employment shall continue in effect
thereafter.

 

(Signature page follows.)

 

    6

     

    

 

IN
WITNESS WHEREOF, this Agreement has been executed by the parties as of the date first above written.

 

	 	ANNOVIS BIO, INC.
	 	 	 
	 	By: 	/s/ Michael Hoffman	 
	 	Name: Michael Hoffman

                    Title: Chairman of the Board 

	 	 
	 	 
	 	/s/ Maria L Maccecchini	 
	 	Maria L. Maccecchini

 

 

    7

     

    

 

EXHIBIT A

 

Certain Definitions

 

The following terms have the meaning set
forth below wherever they are used in this Agreement:

 

“Cause”
for the Company (or a successor, if appropriate) to terminate the Executive’s employment will exist upon the occurrence of
any of the following events: (i) the Executive’s continued failure to substantially perform the Executive’s duties
and obligations to the Company, including but not limited to any material breach of this Agreement or any material violation of
the Company’s written policies or rules, and failure to cure the same within ten business days after being notified by the
Board; (ii) the Executive’s having committed willful fraud or willful misconduct, in any such case which is materially injurious
to the Company; (iii) the Executive’s having been convicted of a felony involving moral turpitude that results in material
harm to the standing or reputation of the Company; or (iv) the Executive’s material breach of the terms of the Confidentiality
and Invention Assignment Agreement.

 

“Change of Control” shall have
the meaning set forth in the Equity Incentive Plan.

 

“Code” means the Internal Revenue
Code of 1986, as amended.

 

“Commencement Date” means March
24, 2020.

 

“Disability” means an illness,
incapacity or a mental or physical condition that renders the Executive unable or incompetent, with or without a reasonable accommodation,
to carry out the job responsibilities that the Executive held or the tasks that the Executive was assigned at the time the disability
commenced for a period of 90 consecutive days, or 180 non-consecutive days in any rolling 12-month period.

 

“Equity Incentive Plan” shall
mean the Company’s 2020 Equity Incentive Plan, as amended and then in effect.

 

“Fully Diluted Equity” means
the issued and outstanding shares of the Company’s Common Stock, determined on a fully-diluted, as-converted basis as of
the date of grant of the applicable stock options, inclusive of all allocated and unallocated shares authorized to be issued under
the Equity Incentive Plan.

 

“Good
Reason” for the Executive to resign from the employ of the Company will exist upon the occurrence of any of the following
events, subject to compliance with the other provisions of Section 4(c): (a) a material reduction in the Base Salary, as
then in effect; (b) a material reduction of the Executive’s authority, position, responsibilities or duties; (c) the Company’s
material breach of this Agreement; or (d) a relocation at the request of the Board of the Executive’s principal workplace
by more than 50 miles from the Company’s principal offices as of the Commencement Date; provided, however, that (i) clause
(a) shall not apply if such reduction is part of a Company-wide reduction in compensation and/or benefits for all of its senior
executives, and (ii) following a Change of Control, a reduction in authority, position, responsibilities or duties solely by virtue
of the Company being acquired and becoming part of a larger entity or operated as a subsidiary shall not constitute Good Reason.

 

    A-1

     

    

 

EXHIBIT B

 

Equity Incentive Awards

 

Pursuant to the terms and conditions of
the Equity Incentive Plan and an appropriate grant agreement to be executed by the Executive and the Company, the Executive shall
be granted the following equity incentive awards in such forms as shall be determined by the Board, upon consultation with the
Executive: (a) on or before April 30, 2020, an equity incentive award of 300,000 shares of the Company’s Common Stock, all
of which shares shall be vested in full upon grant and (b) on or after January 1, 2021 and on or before April 30, 2021, an equity
incentive award of 112,995 shares of the Company’s Common Stock, which shall be vested in full upon grant.

 

In the event the Company raises additional
capital prior to April 30, 2021 through the sale of its securities and the Board determines in its sole discretion that the Executive’s
performance warrants the grant of additional equity incentive awards, the Board shall grant to the Executive an additional equity
incentive award of 165,199 shares of the Company’s Common Stock, subject to approval by the stockholders of the Company
of an increase in the shares available under the Equity Incentive Plan. Such additional equity incentive award shall: (a) be granted
in accordance with the terms and conditions of the Equity Incentive Plan and an appropriate grant agreement to be executed by
the Executive and the Company, and (b) vest in two equal installments on March 30, 2022 and March 30, 2023, respectively, subject
to accelerated vesting of such additional award upon a Change of Control of the Company.

 

 

 

    B-1

     

    

 

EXHIBIT C

 

Release of Claims

 

1.             Termination of Employment. ________________ (“Executive”) hereby agrees and recognizes that, as of _______,
20__, Executive’s employment relationship with Annovis Bio, Inc., a Delaware corporation (the “Company”), will
be permanently and irrevocably severed.

 

2.             Release of Claims. In consideration of the payments and benefits described in Section 4(d) and Section 4(e) of the
employment agreement (the “Employment Agreement”), effective _______, 2020, by and between Executive and the Company,
to which Executive agrees Executive is not entitled until and unless Executive executes and does not revoke this Release, Executive,
for and on behalf of herself and her heirs, executors, administrators and assigns, hereby waives and releases any and all complaints,
claims, suits, controversies, and actions, whether known or unknown, suspected or claimed, which Executive, or any of the Executive’s
heirs, executors, administrators or assigns ever had, now has or may have against the Company and/or its respective predecessors,
successors, past or present parents or subsidiaries, affiliates, investors, branches or related entities (collectively, including
the Company, the “Entities”) and/or the Entities’ past or present stockholders, insurers, assigns, trustees,
directors, officers, limited and general partners, managers, joint venturers, members, employees or agents in their respective
capacities as such (collectively with the Entities, the “Releasees”) by reason of circumstances, acts or omissions
which have occurred on or prior to the date that this Release becomes effective, including, without limitation, (a) any complaint,
charge or cause of action arising under (i) federal, state or local laws pertaining to employment or termination of employment,
including the Age Discrimination in Employment Act of 1967 (the “ADEA,” a law which prohibits discrimination on the
basis of age), the National Labor Relations Act, as amended, the Civil Rights Act of 1991, as amended, the Americans with Disabilities
Act of 1990, as amended, Title VII of the Civil Rights Act of 1964, as amended, the Equal Pay Act of 1963, as amended, the Family
and Medical Leave Act of 1993, as amended, the Worker Adjustment Retraining and Notification Act, as amended, the Executive Retirement
Income Security Act of 1974, as amended, any applicable Executive Order Programs, the Fair Labor Standards Act, or their state
or local counterparts (including, but not limited to, the Pennsylvania Human Relations Act); (ii) any other federal, state or local
civil or human rights law; (iii) any other local, state, or federal law, regulation or ordinance; (iv) any public policy, contract
and/or quasi-contract or tort (including, but not limited to, claims of breach of the Employment Agreement, an expressed or implied
contract, tortious interference with contract or prospective business advantage, breach of the covenant of good faith and fair
dealing, promissory estoppel, detrimental reliance, invasion of privacy, nonphysical injury, personal injury or sickness or any
other harm, wrongful or retaliatory discharge, fraud, defamation, slander, libel, false imprisonment, negligent or intentional
infliction of emotional distress); (v) common law; or (vi) any policies, practices or procedures of the Company; or (b) any claim
for costs, fees, or other expenses, including attorneys’ fees incurred in these matters (the “Released Claims”).
By signing this Release, Executive acknowledges that she intends to waive and release any rights known or unknown that she may
have against the Releasees under these and any other laws. Notwithstanding the foregoing, Executive does not release, discharge
or waive: any rights to indemnification that she may have under the certificate of incorporation, the by-laws or equivalent governing
documents of the Company or its subsidiaries or affiliates, the laws of the State of Delaware or any other state of which any such
subsidiary or affiliate is a domiciliary, the Employment Agreement or any indemnification agreement between Executive and the Company;
any rights to insurance coverage under any directors’ and officers’ personal liability insurance or fiduciary insurance
policy; any rights she may have in her capacity as a stockholder of the Company; any rights she may have to enforce the vested
terms of any equity or other incentive agreement previously provided to her; any rights she may have to severance benefits and
payment of Accrued Obligations under the Employment Agreement (the “Excluded Claims”). The Executive acknowledges that
she has made no assignment or transfer of any right, claim, demand, cause of action, or other matter covered by this Section 1.

 

    C-1

     

    

 

3.             Proceedings. Executive acknowledges that she has not filed any complaint, charge, claim or proceeding, if any, or
assigned to any other person the right to bring any such complaint, charge, claim, or proceeding, relating to the Released Claims
against any of the Releasees before any local, state or federal agency, court or other body (each individually a “Proceeding”).
Executive (i) acknowledges that she will not initiate or cause to be initiated on her behalf any Proceeding and will not participate
in any Proceeding, in each case, except as required by law and (ii) waives any right she may have to benefit in any manner from
any relief (whether monetary or otherwise) arising out of any Proceeding, including any Proceeding conducted by the Equal Employment
Opportunity Commission (the “EEOC”). Further, Executive understands that, by executing this Release, she will be limiting
the availability of certain remedies that she may have against the Releasees and limiting also her ability to pursue certain claims
against the Releasees. Notwithstanding the above, nothing in Section 1 of this Release shall prevent Executive from (i) initiating
or causing to be initiated on the Executive’s behalf any complaint, charge, claim or proceeding against any Releasee before
any local, state or federal agency, court or other body challenging the validity of the waiver of the Executive’s claims
under the ADEA contained in Section 1 of this Release (but no other portion of such waiver), (ii) initiating or participating in
an investigation or proceeding conducted by the EEOC or (iii) reporting possible violations of federal, state or local law, ordinance
or regulation to any governmental agency or entity, including, but not limited to, the Department of Justice, the U.S. Securities
and Exchange Commission (the “SEC”), the Congress and any agency Inspector General, or otherwise taking action or making
disclosures that are protected under the whistleblower provisions of any federal, state or local law, ordinance or regulation,
including, but not limited to, Rule 21F-17 promulgated under the Securities Exchange Act of 1934, as amended; or (iv) receiving
a monetary award for information provided to the SEC pursuant to Rule 21F-17 promulgated under the Securities Exchange Act of 1934,
as amended. The Executive acknowledges and agrees that the Executive’s separation from employment with the Company in compliance
with the terms of the Employment Agreement shall not serve as the basis for any claim or action (including, without limitation,
any claim under the Age Discrimination in Employment Act of 1967).

 

4.             Time
to Consider. Executive acknowledges that she has been advised that she has [twenty-one (21)]/[forty-five (45)]1
days from the date of receipt of this Release to consider all the provisions of this Release and, further, that if
Executive signs this Release prior to the expiration of such [twenty-one (21)]/[forty-five (45)] day period, she does hereby knowingly
and voluntarily waive said given [twenty-one (21)]/[forty-five (45)] day period. EXECUTIVE FURTHER
ACKNOWLEDGES THAT SHE HAS READ THIS RELEASE CAREFULLY, HAS BEEN ADVISED BY THE COMPANY TO, AND HAS IN FACT, CONSULTED AN ATTORNEY,
AND FULLY UNDERSTANDS THAT BY SIGNING BELOW SHE IS GIVING UP CERTAIN RIGHTS WHICH SHE MAY HAVE TO SUE OR ASSERT A CLAIM AGAINST
ANY OF THE RELEASEES, AS DESCRIBED IN SECTION 1 OF THIS RELEASE AND THE OTHER PROVISIONS HEREOF. EXECUTIVE ACKNOWLEDGES THAT SHE
HAS NOT BEEN FORCED OR PRESSURED IN ANY MANNER WHATSOEVER TO SIGN THIS RELEASE, AND EXECUTIVE AGREES TO ALL OF ITS TERMS VOLUNTARILY.
[EXECUTIVE ALSO ACKNOWLEDGES THAT SHE HAS RECEIVED ALL INFORMATION REQUIRED TO BE DISCLOSED IN CONNECTION WITH AN EXIT INCENTIVE
OR OTHER EMPLOYMENT TERMINATION PROGRAM.]

 

5.             Revocation. Executive hereby acknowledges and understands that Executive shall have seven (7) days from the date
of her execution of this Release to revoke this Release (including, without limitation, any and all claims arising under the ADEA)
and that neither the Company nor any other person is obligated to provide any benefits to Executive pursuant to Section 4(d) or
Section 4(e) of the Employment Agreement until eight (8) days have passed since Executive’s signing of this Release without
Executive having revoked this Release, in which event the Company immediately shall arrange and/or pay for any such benefits otherwise
attributable to said eight-(8) day period, consistent with the terms of the Employment Agreement. If Executive revokes this Release,
Executive will be deemed not to have accepted the terms of this Release, no action or forbearance of action will be required of
the Company under any section of this Release, and Executive shall not be entitled to receive any portion of the severance compensation
and benefits which are conditioned on the delivery of this Release.

 

 

 

 

1 NTD: To be selected based on whether applicable termination was “in connection with an exit incentive or other employment termination program” (as such phrase is defined in the Age Discrimination in Employment Act of 1967).

    C-2

     

    

 

6.             No Admission. This Release does not constitute an admission of liability or wrongdoing of any kind by Executive or
the Company.

 

7.             Confidentiality. Executive agrees that Executive will not communicate or disclose the terms of this Release to any
persons with the exception of members of Executive’s immediate family and Executive’s attorney and financial advisor,
or as permitted by Section 3 above.

 

8.             Return of Company Property. Executive represents that all equipment and other property of the Company, including
any documents and files, whether electronically stored or maintained in hard copy, have been returned to the Company, and that
Executive has not retained any copies of the same.

 

9.             Non-Disparagement. Executive will not disparage any Releasee or otherwise take any action which could reasonably
be expected to adversely affect the personal or professional reputation of any Releasee. The Company’s directors, officers
and senior executives shall not disparage or otherwise take any action which could reasonably be expected to adversely affect the
personal or professional reputation of the Executive.

 

10.           Post-Employment Obligations. Executive reaffirms that she will comply with all
of her post-employment obligations as set forth in Section 5 of the Employment Agreement.

 

11.           Entire Agreement. This Agreement constitutes the entire agreement between the parties and supersedes any and all
prior representations, agreements, written or oral, expressed or implied, except for Section 5 of the Employment Agreement, which
survives the termination of Executive’s employment and is incorporated herein by reference, and except for any agreements
with respect to Executive’s options to acquire Common Stock of the Company. This Agreement may not be modified or amended
other than by an agreement in writing signed by an officer of the Company.

 

12.           Acknowledgement. Executive acknowledges and agrees that, subsequent to the termination of Executive’s employment,
Executive shall not be eligible for any payments from the Company or Company-paid benefits, except as expressly set forth in this
Agreement. Executive also acknowledges and agrees that Executive has been paid for all time worked and has received all other compensation
owed to her.

 

13.           Assignment. This Agreement shall be binding upon and be for the benefit of the parties as well as Executive’s
heirs and the Company’s successors and assigns.

 

14.           General Provisions. A failure of any of the Releasees to insist on strict compliance with any provision of this Release
shall not be deemed a waiver of such provision or any other provision hereof. If any provision of this Release is determined to
be so broad as to be unenforceable, such provision shall be interpreted to be only so broad as is enforceable, and in the event
that any provision is determined to be entirely unenforceable, such provision shall be deemed severable, such that all other provisions
of this Release shall remain valid and binding upon Executive and the Releasees.

 

15.           Governing Law. The validity, interpretations, construction and performance of this Release shall be governed by the
laws of the Commonwealth of Pennsylvania without giving effect to conflict of laws principles.

 

IN
WITNESS WHEREOF, Executive has hereunto set Executive’s hand as of the day and year set forth opposite her signature
below.

 

 

	 	 	 
	Date	 	Maria L. Maccecchini

 

    C-3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}]]